Evidence map›Paper›PMID 38770568›Full record

ReviewNeuro-oncology2024

DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.

Rifaquat Rahman, Diana D Shi, Zachary J Reitman, Petra Hamerlik, John F de Groot, Daphne A Haas-Kogan, Alan D D'Andrea, Erik P Sulman, Kirk Tanner, Nathalie Y R Agar and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Article
  3. BKJournal of neuro-oncology · 2026
    Article
  4. Article
  5. Review
  6. Current and emerging therapies in IDH-mutant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  7. Review
  8. Recent Advances in Targeted Therapies for Adult Gliomas.Current neurology and neuroscience reports · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Role of BRCA1 in glioblastoma etiology.Cellular oncology (Dordrecht, Netherlands) · 2024
    Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rifaquat RahmanDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Diana D ShiDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Zachary J ReitmanDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Petra HamerlikDivision of Cancer Sciences, University of Manchester, Manchester, UK.
John F de GrootDivision of Neuro-Oncology, University of California San Francisco, San Francisco, California, USA.
Daphne A Haas-KoganDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Alan D D'AndreaDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Erik P SulmanDepartment of Radiation Oncology, New York University, New York, New York, USA.
Kirk TannerNational Brain Tumor Society, Newton, Massachusetts, USA.
Nathalie Y R AgarDepartment of Neurosurgery and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Christopher L TinkleDepartment of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Ranjit S BindraDepartment of Therapeutic Radiology, Yale University, New Haven, Connecticut, USA.
Minesh P MehtaMiami Cancer Institute, Baptist Hospital, Miami, Florida, USA.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-0774-7700

Funding

Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
Enhancing the efficacy of Radiation Therapy for brainstem glioma by targeting ATMK08CA256045 · NCI · DUKE UNIVERSITY · PI Zachary Reitman · 2022 to 2026
$1.1M
NCI NIH HHS K08 CA256045
6 · The paper itself

Abstract

DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.

Indexed as

Brain NeoplasmsDNA DamageAnimalsConsensusConsensus Statements as TopicDNA RepairGliomaHumansMutationTranslational Research, BiomedicalDDR inhibitorsDNA damage responseDNA repairgliomaradiation therapy

Identifiers

PMID38770568
PMCPMC11300028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.